• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Benjamin L. Maughan, MD, PharmD

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
47 4.9 out of 5 Patient Rating

Languages Spoken: English

Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019, and was selected for the 2019 SWOG Young Investigator Training Course.

Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers. During fellowship he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury) and targeted therapies (such as cabozantinib).

He is the lead physician in a SWOG clinical trial exploring a novel treatment for patients with metastatic papillary kidney cancer.

Clinical Locations

Farmington Health Center

801-213-3200

165 N. University Ave.
Farmington, UT  84025
Map

Huntsman Cancer Hospital

801-585-0250

1950 Circle of Hope
Salt Lake City, UT  84112
Map

Specialties

  • Urologic Oncology
  • Genitourinary Cancers
  • Genitourinary Oncology

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Learn About Our Survey

Likelihood of recommending care provider

4.9/ 5

Care provider's explanation of condition/problem

4.9/ 5

Care provider's effort to include me in decisions

4.9/ 5

Wait time at clinic

4.5/ 5

Care provider's concern for questions & worries

4.9/ 5

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

UofU Patient October 23, 2022
Farmington Health Center

5 out of 5 stars

Dr Maughn is a wonderful doctor. Great listener and always spends as much time is needed during appt. I have never ever felt rushed I consider my care with Dr Maughn's team to be exceptional and consider myself very lucky

UofU Patient October 21, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Provide written notes for the consultation

UofU Patient September 04, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

Absolutely recommend Dr Maughan and Lindsay to anyone with cancer.

UofU Patient September 03, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr Maughan and his staff are wonderful

UofU Patient August 18, 2022
FARMINGTON HEALTH CENTER

4 out of 5 stars

Good experience

UofU Patient July 03, 2022
FARMINGTON HEALTH CENTER

4 out of 5 stars

As many of the options as were as available to be discussed

UofU Patient June 06, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

I feel lucky to have Dr Maughan on my side as travel this journey. Him and his staff have made this crazy year much easier. So easy in fact that we could smile and laugh even during the hard parts. Thank you to Dr Maughan and the team, they are rockstars!

UofU Patient May 31, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

We just love Dr Maughn

UofU Patient April 30, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very impressed with everyone individually and with how well they worked together.

UofU Patient April 09, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr Maughn was very attentive and answered my questions I had at the time

UofU Patient March 06, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

I appreciate the care I receive from my team. I don't think I would be in the mental and physical state I'm in now without the team I have.

UofU Patient February 06, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

I appreciate the care and concern Dr Maughan shows for me. He listens to all my questions and problems. I totally trust my team.

UofU Patient January 31, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

Dr Maughan and his staff are excellent in their knowledge and skills. Dr Maughan always takes time to thoroughly discuss all aspects of care with me. Let's me know what medicine is available and the benefits and side affects.

UofU Patient January 30, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

I can't say enough good things about Dr. Maughan. He always listens. Is very thoughtful and is superb at explaining complex matters.

UofU Patient January 21, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

We love Dr. Maughn!

UofU Patient January 10, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

There is only good experiences

UofU Patient January 09, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

Again, these people are amazing! They have been with me through the hard times and the good. It's weird when you just about die. Your whole life seems different and it's an experience that's hard to explain, but everyone in this office has encouraged me through it and it's so fun to have a group of people that will cheer with you, and understand it all with you. I genuinely love this office.

UofU Patient January 09, 2022
FARMINGTON HEALTH CENTER

5 out of 5 stars

I appreciate the way Dr Maughan explains my scans and answers all my questions fully. I have total trust in my team

UofU Patient December 03, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Once again Dr Maughan was superb

UofU Patient November 14, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very well informed.

UofU Patient November 07, 2021
FARMINGTON HEALTH CENTER

5 out of 5 stars

Dr Maughan is a great Dr. He always explains my treatments or changes so I understand completely what's going on. He always listens to my concerns or questions. I have total trust and confidence in him snd his staff.

UofU Patient November 07, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Once again Dr. Maughan and his team showed great concern and answered all of my questions

UofU Patient October 13, 2021
FARMINGTON HEALTH CENTER

5 out of 5 stars

I appreciate the way Dr Maughan treats me. He is always concerned about how I feel and listens to me. He explains all my treatments and situations so I understand fully what my options are. I enjoy all my visits with him and I trust him completely.

UofU Patient September 17, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. Maughan is great so glade to have him !!!!

UofU Patient September 12, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr is always able to fully explain any changes to my condition and in a way that I can understand. Dr Maughn and His staff always takes care of any Issues or questions I have.

UofU Patient September 09, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr Maughan Awesome

UofU Patient July 31, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

So concerned about a side effect I was experiencing, there was a temporary change. Their concern for me was very high. Included a followup phone call.

UofU Patient July 09, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Personal time with all providers was beyond adequate; very informative and helpful to my frame of mind.

UofU Patient July 02, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Once again Dr Maughan was superb in listening and answering questions

Benjamin Maughan MD, PharmD is an Assistant Professor in the Division of Medical Oncology at Huntsman Cancer Institute specializing in genitourinary malignancies. Dr. Maughan completed his PharmD, cum laude, from Idaho State University in 2004, then completed an oncology pharmacy residency at Mountain States Tumor Institute in 2005. Dr. Maughan earned his MD, cum laude, from the University of Kentucky, College of Medicine in 2010. He finished his Internal Medicine residency training with the University of Utah in 2013 and subsequently completed his medical oncology fellowship at Johns Hopkins in 2016. He has been awarded the Huntsman Cancer Institute Translational Scholar Award in 2019, and was selected for the 2019 SWOG Young Investigator Training Course.

Dr. Maughan has clinical and research interests in all genitourinary oncology, with a particular focus on the development of novel therapeutics and in identification of predictive biomarkers. During fellowship he studied predictive biomarkers in metastatic prostate cancer, specifically the role of truncated androgen receptors (AR-V7 expression) and loss of tumor suppressors (PTEN and Rb). More recently he is studying predictive biomarkers to immune therapy combinations in kidney, bladder and prostate cancers. He is exploring novel immune therapy combinations including checkpoint inhibitors combined with radiation therapy (radium-223), oncolytic viruses (MVA-brachyury) and targeted therapies (such as cabozantinib).

He is the lead physician in a SWOG clinical trial exploring a novel treatment for patients with metastatic papillary kidney cancer.

Academic Locations

Primary Children’s and Families’ Cancer Research Center

801-585-0255

2000 Circle of Hope
Division of Oncology, 5617
Salt Lake City, UT  84112

Board Certification and Academic Information

Academic Departments Internal Medicine - Assistant Professor
Academic Divisions Oncology
Board Certification American Board of Internal Medicine (Internal Medicine)
American Board of Internal Medicine (Sub: Medical Oncology)

Research Interests

  • Development of Predictive Biomarkers of Response to Therapy
  • Novel Therapeutic Development in Genitourinary Cancers
  • Molecular Diagnostics
  • Immunotherapy in Genitourinary Cancers

Education History

Fellowship Johns Hopkins University
Medical Oncology
Fellow, 2016
Residency University of Utah School of Medicine
Internal Medicine
Resident, 2013
Professional Medical University of Kentucky College of Medicine
Medicine
M.D., 2010
Residency St. Luke's Mountain States Tumor Institute
Oncology Pharmacy
Resident, 2005
Doctoral Training Idaho State University College of Pharmacy
Pharmacy
Pharm.D., 2004

Selected Publications - Journal Articles

Journal Article

  1. Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N (2022). External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate Cancer. Mol Cancer Ther, 21(12), 1857-1861.
  2. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol, 40(11), 493.e1-493.e7.
  3. Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC (2022). Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist, 27(10), e815-e818.
  4. Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N (2022). Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol, 12, 966534.
  5. Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583.
  6. Sonpavde GP, Maughan BL, McGregor BA, Wei XX, Kilbridge KL, Lee RJ, Yu EY, Schweizer MT, Montgomery RB, Cheng HH, Hsieh AC, Jain R, Grewal JS, Pico-Navarro C, Gafoor Z, Perschy T, Grivas P (2022). Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma. Cancer Immunol Immunother.
  7. Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S (2022). Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol, 23, 899-909.
  8. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, MK-6482-004 Investigators (2021). Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med, 385(22), 2036-2046.
  9. Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, Maughan BL, Rathi N, Sirohi D, Nussenzveig R, Kohli M, Pal SK, Agarwal N (2021). Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers (Basel), 13(19).
  10. Pal SK, McGregor B, Surez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N (2021). Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol, 39, JCO2100939.
  11. Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK (2021). Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clin Cancer Res, 27(17), 4807-4813.
  12. Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N (2021). Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 26(9), 751-760.
  13. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 26, 1006-e2129.
  14. Maughan BL, Antonarakis ES (2021). Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. Expert Opin Pharmacother, 22(12), 1625-1632.
  15. Brundage J, Maughan BL (2021). New models for defining prostate cancer biology and patient prognosis. Asian J Androl, 24, 119-120.
  16. Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N (2020). Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma. J Urol, 205(3), 709-717.
  17. Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES (2020). Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. Oncologist, 26(2), e270-e278.
  18. McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, Zakharia Y, Maughan BL, Rose TL, Stadler WM, McDermott DF, Harshman LC, Choueiri TK (2020). Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). J Clin Oncol, 38(36), 4240-4248.
  19. Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (2020). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol, 78(5), 652-656.
  20. Kaur H, Samarska I, Lu J, Faisal F, Maughan BL, Murali S, Asrani K, Alshalalfa M, Antonarakis ES, Epstein JI, Joshu CE, Schaeffer EM, Mosquera JM, Lotan TL (2020). Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. Prostate, 80(12), 1012-1023.
  21. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6.
  22. Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M (2020). Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clin Cancer Res, 26(11), 2546-2555.
  23. Rathi N, Maughan BL, Agarwal N, Swami U (2020). Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Manag Res, 12, 3741-3749.
  24. Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res, 26(9), 2104-2110.
  25. Maughan BL, Antonarakis ES (2020). Does sequencing order of antiandrogens in prostate cancer matter? Nat Rev Urol, 17(4), 197-198.
  26. Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L, Agarwal N, Cooney KA (2020). Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precis Oncol, 4.
  27. Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist, 25(2), 121-e213.
  28. Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M (2020). CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precis Oncol, 4, 370-381.
  29. Esther J, Dorff TB, Maughan BL (2020). Recent developments in the treatment of non-metastatic castration resistant prostate cancer. Cancer Treat Res Commun, 24, 100181.
  30. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098.
  31. Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N (2019). A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. Oncologist.
  32. Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL (2019). Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs Aging, 36(5), 395-401.
  33. Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N (2018). Germline Variant in SLCO2B1 and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Mol Cancer Ther, 18(3), 726-729.
  34. Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW (2019). Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Curr Treat Options Oncol, 20(2), 14.
  35. Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N (2019). Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS One, 14(1), e0210415.
  36. Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N (2018). Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treat Res Commun, 19, 100116.
  37. Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N (2019). Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treat Res Commun, 19, 100120.
  38. Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N (2018). Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. Oncologist, 23(12), 1413-e151.
  39. Sirohi D, Smith SC, Agarwal N, Maughan BL (2018). Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Res Rep Urol, 10, 205-217.
  40. Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL (2018). p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 21(2), 260-268.
  41. Gill DM, Hahn AW, Hale P, Maughan BL (2018). Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options Oncol, 19(1), 6.
  42. Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL (2018). p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis, 10.1038(s41391-017).
  43. Hahn AW, Gill DM, Agarwal N, Maughan BL (2017). PD-1 checkpoint inhibition: toxicities and management. Urol Oncol, 10.1016(35(12)), 701-701.
  44. Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N (2017). Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clin Genitourin Cancer, S1558-7673(10.1016/j.).
  45. Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Antonarakis ES (2017). Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Int J Urol, 24(6), 441-448.
  46. Harshman LC, Werner L, Tripathi A, Wang X, Maughan BL, Antonarakis ES, Nakabayashi M, McKay R, Pomerantz M, Mucci LA, Taplin ME, Sweeney CJ, Lee GM, Kantoff PW (2017). The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate, 77(13)(10.1002/pr), 1303-1311.
  47. Maughan BL, Luber B, Nadal R, Antonarakis ES (2017). Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. Prostate, 77(1), 33-40.
  48. Maughan BL, Suzman DL, Luber B, Wang H, Glavaris S, Hughes R, Sullivan R, Harb R, Boudadi K, Paller C, Eisenberger M, Demarzo A, Ross A, Antonarakis ES (2016). Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol, 78(6), 1297-1304.
  49. Maughan BL, Antonarakis ES (2015). Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Curr Treat Options Oncol, 16(12), 57.
  50. Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES (2015). Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate, 75(15), 1814-20.
  51. Maughan BL, Antonarakis ES (2014). Enzalutamide in chemo-naive castration-resistant prostate cancer: effective for most but not for all. Asian J Androl, 16(6), 807-8.
  52. Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G (2014). Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 12(2), 130-7.
  53. Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G (2013). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer, 11(3), 316-20.
  54. Patel JC, Maughan BL, Agarwal AM, Batten JA, Zhang TY, Agarwal N (2013). Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer, 2013, 981684.

Review

  1. Li H, Sahu KK, Maughan BL (2022). Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. [Review]. Cancers (Basel), 14(10).
  2. Maughan BL (2022). Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022. [Review]. Curr Oncol Rep, 24, 1201-1208.
  3. Maughan BL, Antonarakis ES (2015). Androgen pathway resistance in prostate cancer and therapeutic implications. [Review]. Expert Opin Pharmacother, 16(10), 1521-37.

Case Report

  1. McComas K, Agarwal N, Bowen G, Maughan BL, Tward JD (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clin Genitourin Cancer, 18(5), e573-e584.

Editorial

  1. Rathi N, Maughan BL, Agarwal N, Swami U (2019). The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. Transl Cancer Res, 8(8), E1-E6.
  2. Maughan BL, Eisenberger MA (2016). A Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks? Eur Urol, 70(5), 732-733.

Letter

  1. Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N (2019). Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. [Letter to the editor]. J Geriatr Oncol, 11(4), 724-726.

Abstract

  1. P Twardowski, J YCWong, SKPal, B LMaughan, P H Frankel, K Franklin, M Junqueira, M RPrajapati, G Nachaegari, D Harwood, N Agarwal (12/28/2018). Randomized phase II trial of Sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer [Abstract]. Cancer Treatment and Research Communications (doi: 10.1016/j.ctarc.2018.100116), 20 December 2018, 100116.
  2. Sirohi D, Smith SC, Agarwal N, Maughan BL (November 2018). Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities [Abstract]. Dove Medical Press, 2018(10), 205-217.
  3. Maughan BL, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES (2015). Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) [Abstract]. J Clin Oncol, 33(Suppl 7), abstr 252.

Huntsman Cancer Institute News

Ask an Expert: Kidney Cancer

Translational Scholar: Benjamin L. Maughan, MD, PharmD

Department News

HemOnc Today honors Next Gen Innovators at ASCO

Taylor Endowment Research Award

Site Links

  • Find an Interpreter
  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • Referring Providers

Helpful Links

  • Price Estimate
  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Surprise Billing Rights
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

Appointment Scheduling:
801-213-9500

Hospital Operator:
801-581-2121

En Español:
801-646-5914

  • Facebook
  • Twitter
  • Youtube
  • Instagram

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2023 University of Utah Health